Publications
Specialty
Search
Pharmacy Learning Network
06/14/2024
At the very end of May 2024, pharmaceutical manufacturer Novo Nordisk announced the filing of 9 new lawsuits against medical spas, weight loss clinics, pharmacies, and others in Colorado, Florida, Illinois, Montana, Tennessee, and Texas.
First Report Managed Care
06/14/2024
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Psych Congress Network
06/14/2024
Do you remember this study?
Journal of Invasive Cardiology, CardioVascular
06/14/2024
The authors report a late-diagnosed APW in a 4-year-old male with high pulmonary arterial pressure and high pulmonary vascular resistance index who was initially treated with transcatheter device closure as a bridge for surgical repair.
Oncology
06/14/2024
In this video, a panel of experts discuss the management of patients with HER2-low metastatic breast cancer, sharing data from the DESTINY-Breast06 trial.
Gastroenterology
06/14/2024
The first-in-class PPAR is the first new medicine approved in nearly a decade for primary biliary cholangitis.
The Dermatologist
06/14/2024
A novel checklist, known as the, “When to Start Systemic Therapy Checklist,” has been developed to assist dermatology providers in determining when to initiate systemic therapy for patients with atopic dermatitis.
Oncology
06/14/2024
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Gastroenterology
06/14/2024
Kayla Monks, MS, RD, discusses nutritional needs and challenges of patients with liver disease, including candidates for transplant, and how to work with patients to achieve the best possible outcomes.
The Dermatologist
06/13/2024
A recent study has shed light on the efficacy and safety of ruxolitinib cream among adolescents grappling with atopic dermatitis.
Oncology
06/13/2024
Based on results from the LIBRETTO-001 and the LIBRETTO–121 studies, the FDA has approved selpercatinib for adult and pediatric patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.
EP Lab Digest
06/13/2024
Collaboration aims to accelerate speed to diagnosis and treatment of hypertrophic cardiomyopathy
Neurology, Psych Congress Network
06/13/2024
Adolescents with higher levels of adiposity may be more susceptible to the cognitive effects of sleep restriction than those with lower adiposity, according to a recent single-blind randomized crossover trial.
Oncology
06/13/2024
Jakub Svoboda, MD, discusses preliminary research that examines the safety and efficacy of armored huCART19-IL18 among patients with relapsed/refractory non-Hodgkin lymphoma that progressed after anti-CD19 CAR T-cells.
Oncology
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
Pharmacy Learning Network
06/13/2024
GlaxoSmithKline LLC is recalling 463 cartons of Tivicay PD because the product box lists incorrect expiration information.
Pharmacy Learning Network
06/13/2024
Bryant Ranch Prepack Inc. is recalling 456 bottles of cephalexin for oral suspension due to various labeling errors.
Oncology
06/13/2024
According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant ovarian cancer.
The Dermatologist
06/13/2024
Researchers aimed to explore the roles of anti-inflammatory diets and fecal microbiota transplant in PsA management.
Oncology
06/13/2024
Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung cancer who had baseline N2 nodal status.